News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Asembia 2025 |
Sales Effectiveness|
Latest Executive Roundtables
Advertisement

Rujul Desai

Advertisement

Articles by Rujul Desai

i4-808516-1408547154518.jpg

Specialty Service Programs: Gearing up for Next Generation Technologies

ByRujul Desai,Partha Anbil
March 1st 2013

Innovation in hub program design for patient scrip data and clinical support services can lead to increased market share in the hotly contested specialty medicine space.

Advertisement

Latest Updated Articles

  • i4-808516-1408547154518.jpg
    Specialty Service Programs: Gearing up for Next Generation Technologies

    Published: March 1st 2013 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

Organon CEO Kevin Ali to Resign Following Internal Investigation into Nexplanon Sales

2

Study Claims Ozempic Lowers Biological Age

3

GSK Agrees to $357 Million Exclusive License Agreement for Syndivia’s AntiBody-Drug Conjugate

4

Pharmaceutical Executive Daily: New Research Suggests Ozempic May Reduce Biological Age

5

Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us